-
Ukoniq FDA Advisory Committee Meeting in April 2022 Will Evaluate Ukoniq Drug Safety Findings
FDA Has Been Investigating Ukoniq for an Increased Risk of Death in Lymphoma Cancer Patients Treated With Ukoniq (Posted by Tom Lamb at Drug Injury Watch) UPDATE: Ukoniq Drug Recall in April 2022 Comes Soon After…
-
How People Can Report Adverse Drug Reactions to the FDA, and What Happens to This Information Thereafter
From time to time we hear from people who want to know: (1) How they can report a serious prescription drug side effect, or adverse drug reaction, to the FDA; and, (2) What happens…
-
JAK Inhibitors Safety Review by European Drug Regulator EMA Announced in February 2022
Xeljanz, Rinvoq, and Olumiant as Treatments for Inflammatory Disorders Have Been Under Scrutiny by FDA in the US (Posted by Tom Lamb at Drug Injury Watch) In December 2021 there was a notable JAK inhibitors…
-
Ukoniq Lymphoma Drug Safety Investigation Started In February 2022 to Examine Increased Risk of Death
FDA Oncologic Drugs Advisory Committee Meeting in Near Future May Consider Possible Ukoniq Drug Recall (Posted by Tom Lamb at Drug Injury Watch) UPDATE: Ukoniq Drug Recall in April 2022 Comes Soon After FDA Warning…
